GHO Capital raises €975m in largest ever European healthcare fund
GHO Capital raises €975m in largest ever European healthcare fund
GHO Capital Partners LLP, the European specialist investor in healthcare, has announced the final close of GHO Fund II LP at its hard cap of €975m. The Fund represents the largest specialist private equity fund dedicated to European healthcare.
Approximately 50% larger than the firm’s maiden fund raised in 2015, Fund II was significantly oversubscribed, exceeding a target of €800m. Since it was founded in 2014, GHO has grown its total assets under management (AUM) to €2bn, making it Europe’s largest healthcare-dedicated investment firm. The fund will invest in high growth healthcare subsectors, including pharmaceuticals, medical technology and outsourced services.
The Fund aims to develop the significant untapped market opportunity within specialist, high-growth healthcare subsectors, including pharma, medtech and outsourced services, through growth buyout investments. The target market is underpinned by strong structural drivers characterised by widespread demand for better, faster and more accessible healthcare.
With a pan-European focus, the Fund also has the capability to draw upon GHO’s extensive international network to capture and accelerate transatlantic growth opportunities. Within the last six months, GHO exited investments in Caprion Biosciences and Quotient Sciences, having successfully leveraged organic and inorganic growth opportunities to create transatlantic sector leaders.
GHO invests alongside strong management teams, bringing unrivalled sector expertise and a network of unparalleled industry reach, helping to drive operational improvements and source bolt-on opportunities globally.
Fund II has already made two investments in Q1 2019, investing alongside management in Sterling Pharma Solutions, a leading provider of small molecule API development and manufacturing services to the global pharmaceutical industry, as well as in BioAgilytix, an independent global provider of large molecule bioanalytical testing solutions.
Rede is delighted to have acted as fundraising advisor for this fundraise having also advised on GHO Fund I LP which closed at its €660m hard cap in November 2016.
